Curriculum vitae

PERSONAL INFORMATION Valentina Mantua

WORK EXPERIENCE

September 2012–Present Senior assessor, Agenzia Italiana del Farmaco, AIFA, Via del Tritone 181, Roma, Italy. Member, CHMP Central Nervous System Working Party, European Medicines Agency, London, UK Italian Representative, EU Innovation Network, European Medicines Agency, London, UK Principal Site Investigator, SWITCHItalian Medicines Agency (AIFA) (Italy)

Involved in AIFA activities on CNS drugs assessment

- Clinical expert in Research and Development Working Group, AIFA

- Clinical Assessor in centralised procedures (working for the IT CHMP member)

- Italian Team alternate member at Scientific Advice Working Party (SAWP), EMA

- Member at CNS Working Party, EMA

August 2008–December 2008 Medical doctorPrivate Practice (Italy)

Health Care - Clinical Adult Psychiatry

January 2009–June 2012 PHD CandidateDepartment of Psychiatry, Neurobiology, Pharmacology and Biotechnology, University of Pisa (Italy)

PhD in Neurobiology and Clinical of Affective Disorders

November 2004–July 2007 Clinical Research WorkerInstitute of Psychiatry Kings College London (United Kingdom)

Clinical Research in Psychiatry

January 2006–July 2007 Associate SpecialistSouth London and Maudsley Foundation Trust (United Kingdom)

NHS Outpatients Community First Episode Psychosis Service Croydon -

Attending young (18-30 years of age) patients with first episode psychosis 3,5 sessions/week

EDUCATION AND TRAINING

November 2000–November 2004 Specialist in PsychiatryUniversity of Rome Sapienza (Italy)

Full Training in General Adult Psychiatry

January 1994–October 2000 Degree in Medicine and SurgeryUniversity of Rome Sapienza (Italy)

Medicine and Surgery

Final dissertation in Psychiatry

January 2009–June 2012 PhD in Neurobiology and Clinic of Affective DisordersUniversity of Pisa (Italy)

11/1/18 © European Union, 2002-2017 | http://europass.cedefop.europa.eu Page 1 / 3

Curriculum vitae Valentina Mantua

November 2014–October 2015 Advanced Continuing Education CourseUniversity Sapienza Rome (Italy)

Economy and Healthcare Management

ADDITIONAL INFORMATION

Expertise Clinical assessment of centralized procedure applications, EMA scientific advice reports with role as coordinator, national scientific advice coordinator, rapporteurship of EMA guidelines, coordination of parallel scientific advice and HTA procedures, clinical consultant for HTA evaluations for price and reimbursement of medicines, clinical evaluation of clinical trial applications as national competent authority, strategic support to innovation at a national and European level. Main areas of interest: Alzheimer’s disease, depression, schizophrenia, bipolar disorder, autism, epilepsy, sleep disorders, migraine, pain.

Publications Loth E, Spooren W, Ham LM, Isaac MB, Auriche-Benichou C, Banaschewski T, Baron-Cohen S, Broich K, Bölte S, Bourgeron T, Charman T, Collier D, de Andres-Trelles F, Durston S, Ecker C, Elferink A, Haberkamp M, Hemmings R, Johnson MH, Jones EJ, Khwaja OS, Lenton S, Mason L, Mantua V, Meyer-Lindenberg A, Lombardo MV, O'Dwyer L, Okamoto K, Pandina GJ, Pani L, Persico AM, Simonoff E, Tauscher-Wisniewski S, Llinares-Garcia J, Vamvakas S, Williams S, Buitelaar JK, Murphy DG. Identification and validation of biomarkers for autism spectrum disorders. Nat Rev Drug Discov. 2016 Jan;15(1):70-3.

Haas M, Mantua V, Haberkamp M, Pani L, Isaac M, Butlen-Ducuing F, Vamvakas S, Broich K. The European Medicines Agency's strategies to meet the challenges of Alzheimer disease. Nat Rev Drug Discov. 2015 Apr;14(4):221-2. PMID:

Bradley P, Akehurst R, Ballard C, Banerjee S, Blennow K, Bremner J, Broich K, Cummings J, Dening K, Dubois B, Klipper W, Leibman C, Mantua V, Molinuevo JL, Morgan S, Muscolo LA, Nicolas F, Pani L, Robinson L, Siviero P, van Dam J, Van Emelen J, Wimo A, Wortmann M, Goh L. Taking stock: A multistakeholder perspective on improving the delivery of care and the development of treatments for Alzheimer's disease. Alzheimers Dement. 2015 Apr;11(4):455-61.

Schneider LS, Mangialasche F, Andreasen N, Feldman H, Giacobini E, Jones R, Mantua V, Mecocci P, Pani L, Winblad B, Kivipelto M. Clinical trials and late-stage drug development for Alzheimer's disease: an appraisal from 1984 to 2014. J Intern Med. 2014 Mar;275(3):251-83.

Giusti L, Mantua V, Da Valle Y, Ciregia F, Ventroni T, Orsolini G, Donadio E, Giannaccini G, Mauri M, Cassano GB, Lucacchini A. Search for peripheral biomarkers in patients affected by acutely psychotic bipolar disorder: a proteomic approach. Mol Biosyst. 2014 Jun;10(6):1246-54.

Callari A, Mantua V, Miniati M, Benvenuti A, Mauri M, Dell'osso L. Manic episode after ventricular-peritoneal shunt replacement in a patient with radiation-induced hydrocephalus: the role of lifetime subthreshold bipolar features. Case Rep Psychiatry. 2014;2014:953728.

Vellas B, Carrillo MC, Sampaio C, Brashear HR, Siemers E, Hampel H, Schneider LS, Weiner M, Doody R, Khachaturian Z, Cedarbaum J, Grundman M, Broich K, Giacobini E, Dubois B, Sperling R, Wilcock GK, Fox N, Scheltens P, Touchon J, Hendrix S, Andrieu S, Aisen P; EU/US/CTAD Task ForceMembers. Designing drug trials for Alzheimer's disease: what we have learned from the release of thephase III antibody trials: a report from the EU/US/CTAD Task Force. Alzheimers Dement. 2013 Jul;9(4):438-44.

Cassano GB, Mantua V, Fagiolini A. Bipolar spectrum: just broadening or an integration between categories and dimensions? World Psychiatry. 2011 Oct;10(3):192-3.

Calugi S, Cassano GB, Litta A, Rucci P, Benvenuti A, Miniati M, Lattanzi L, Mantua V, Lombardi V, Fagiolini A, Frank E. Does psychomotor retardation define a clinically relevant phenotype of unipolar depression? J Affect Disord. 2011 Mar;129(1-3):296-300.

Kreczmanski P, Heinsen H, Mantua V, Woltersdorf F, Masson T, Ulfig N, Schmidt-Kastner R, Korr H, Steinbusch HW, Hof PR, Schmitz C. Microvessel length density, total length, and length per neuron in five subcortical regions in schizophrenia. Acta Neuropathol. 2009 Apr;117(4):409-21.

Kreczmanski P, Heinsen H, Mantua V, Woltersdorf F, Masson T, Ulfig N, Schmidt-Kastner R, Korr H, Steinbusch HW, Hof PR, Schmitz C. Volume, neuron density and total neuron number in five subcortical regions in schizophrenia. Brain. 2007 Mar;130(Pt 3):678-92.

V. Mantua, F. Pacitti, M. Peronti, P. Pancheri. MMPI Minnesota Multiphasic Personality Inventory) e scala D (depressione) in pazienti con depressione maggiore: differenza tra maschi e femmine.

11/1/18 © European Union, 2002-2017 | http://europass.cedefop.europa.eu Page 2 / 3

Curriculum vitae Valentina Mantua

Giornale Italiano di Psicopatologia (Italian Journal of Psychopathology), 1999;5(4): 460-465.

M. Biondi, V. Mantua. Le terapie di rilassamento e il rilassamento attivo in psichiatria e in medicina psicosomatica. Medicina Psicosomatica, 2001, 46(3):91-108.

P.P. Colombo, V. Mantua. Il Disturbo Post Traumatico da Stress nella vita quotidiana. Rivista Italiana diPsichiatria, 2001;36(2):55-68.

G.D. Kotzalidis, A. Facchi, L. Tarsitani, V. Mantua, P.P. Colombo, P. Pancheri. Thalamic abnormalities in schizophrenia. Giornale Italiano di Psicopatologia (Italia Journal of Psychopathology), 2001;7(2):134-164.

Chapters in books V. Mantua, F. Di Fabio. Gli effetti collaterali degli SSRI. Pp 121-141. In: C. Loriedo, F. Di Fabio, G. Vella (Eds.). Gli SSRI nella pratica clinica. Masson S.p.A. Milano, 2001

Mantua V. Umori, Emozioni e Profili Comportamentali del Caso Stamina. In: Corbellini G., Capocci M (A cura di). Le Cellule della Speranza. Il Caso Stamina tra Inganno e Scienza. Codice Ed. Torino 2014.

Books V. Mantua . La Salute del Futuro (The future of healthcare), EDRA, Milan 2017

Abstracts in

Peer-Reviewed Journals V. Mantua, A.M. Myint, M Kubera, M. Maes. Effect of different neurochemicals on peripheral BDNF production. European Neuropsychopharmacology, 2004, 13 (suppl.1), S51-52.

V. Mantua, M.J. Travis, Z. Atakan, M.B. Isaac, M.T. Isaac, S. Smith, D. Gilbert, J. Komeh, A. Shaw, C. Sweeney and R.W. Kerwin, Treatment of agitation caused by severe mental illness: data from the South London and Maudsley intensive care units trial evaluation (SLAMICUTE) study. European Neuropsychopharmacology, Volume 16, (Suppl)4, 2006:420-421.

V. Mantua, M.J. Travis, Z. Atakan, M.B. Isaac, M.T. Isaac, D. Gilbert, J. Komeh, A. Shaw, C. Sweeney,R.W. Kerwin. Preliminary data from the London and Maudsley Intensive Care Units Trial Evaluation (SLAMICUTE) Study. Biological Psychiatry, 2006, 59 :218S

Mantua V, Travis MJ, Atakan Z, Isaac MB, Isaac MT, Smith S, Gilbert D, Komeh J, Shaw A, Sweeney C, Kerwin RW. Treatment of agitation caused by severe mental illness: data from the South London and Maudsley Intensive Care Units Trial Evaluation (SLAMICUTE) Study. Journal of Psychopharmacology. 2006; 20 (5): A22.

P. Kreczmanski, H. Heinsen, V. Mantua, F. Woltersdorf, T. Masson, N. Ulfig, R. Schmidt-Kastner, Hubert Korr, H.W.M. Steinbusch, P.R. Hof and C. Schmitz. Volume, neuron density, and total neuron number in five subcortical regions in schizophrenia. Brain. 2007 Mar;130(Pt 3):678-92.

V. Mantua, M.J. Travis, Z. Atakan, M.B. Isaac, M.T. Isaac, D. Gilbert, J. Komeh, A. Shaw, C. Sweeney,R.W. Kerwin. As required medications versus behavioural intervention in the treatment of agitation caused by severe mental illness: data from the South London and Maudsley Intensive Care Unit Trial Evaluation (SLAMICUTE) Study. Schizophrenia Bullettin. 2007; 33(2):443-4.

V. Mantua, M.J. Travis, Z. Atakan, M.B. Isaac, M.T. Isaac, D. Gilbert, J. Komeh, A. Shaw, C. Sweeney,R.W. Kerwin. The SLAMICUTE Study: An evaluation of incident management strategies in an intensive care setting. Journal of Psychopharmacology. 2007; 21(7):A63.

V. Mantua, M.J. Travis, Z. Atakan, M.B. Isaac, M.T. Isaac, D. Gilbert, J. Komeh, A. Shaw, C. Sweeney,R.W. Kerwin. The SLAMICUTE Study: A naturalistic study on pharmacological treatment of agitation in non consenting patients admitted to a UK psychiatric intensive care unit (PICU). Journal of Psychopharmacology. 2008; 22(5):A23.

Projects Principal Site Investigator, SWITCHING VERSUS AUGMENTATION IN TREATMENT RESISTANT DEPRESSION. Fondazione Santa Lucia, Roma, in collaboration with Massachusetts General Hospital, Boston, USA; funded by PCORI

Memberships Member, CHMP Central Nervous System Working Party, European Medicines Agency, London, UK

Italian Representative, EU Innovation Network, European Medicines Agency, London, UK

Other Relevant Information

11/1/18 © European Union, 2002-2017 | http://europass.cedefop.europa.eu Page 3 / 3